3UK Prospective Diabetes Study Group.Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes:UKPDS 39.BMJ,1998,317:713-720.
4Hansson L,Lindholm LH,Niskanen L,et al.Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension:the Captopril Prevention Project (CAPPP) randomised trial.Lancet,1999,353:611-616.
5LIFE Study Group.Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE):a randomised trial against atenolol.Lancet,2002,359:995-1003.
6ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group.Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic:The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).JAMA,2002,288:2981-2997.
7Fournier A,Messerli FH,Achard JM,et al.Cerebroprotection mediated by angiotensin Ⅱ:a hypothesis supported by recent randomized clinical trials.J Am Coll Cardiol,2004,43:1343-1347.
8Fournier A,Achard JM,Boutitie F,et al.Is the angiotensin Ⅱ Type 2 receptor cerebroprotective? Curr Hypertens Rep,2004,6:182-189.
9Epstein BJ,Gums JG.Can the renin-angiotensin system protect against stroke? A focus on angiotensin Ⅱ receptor blockers.Pharmacotherapy,2005,25:531-539.
10Joseph L,Henry R.Hypertension Primer.2nd ed.Baltimore:Lippincott Williams & Wilkins,1999.377-378.
二级参考文献21
1Pitt B,Segal R.Martinez FA,et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE).Lancet, 1997,349:747-752.
2Pitt B,Poole-Wilson PA,Segal R,et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II.Lancet, 2000,355:1582-1587.
3Daholof B,Devereux RB,Kjeldsen SE,et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.Lancet,2002,359:995-1003.
4Lewis EJ,Hunsicker LG,Clarke WR,et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.N Engl J Med, 2001,345:851-860.
5Circulation, 2002;106:672.
6Parving HH,Lehnert H,Brochner-Mortensen J,et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.N Engl J Med, 2001,345:870-878.
7Brenner BM,Cooper ME,de Zeeuw D,et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.N Engl J Med. 2001 Sep 20;345(12):861-869.
8Lithell H,Hansson L,Skoog I,et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial.J Hypertens, 2003,21:875-886.
9ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Groop. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lo
10Wong M,Staszewsky L,Latini R,et al. Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study.J Am Coll Cardiol, 2002,40:970-975.
